35
Participants
Start Date
June 23, 2016
Primary Completion Date
June 1, 2022
Study Completion Date
September 8, 2023
Molecular Microscope Diagnostic system
Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
Cross Cancer Institute, Edmonton
Transplant Genomics, Inc.
INDUSTRY
AHS Cancer Control Alberta
OTHER